GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » ROE % Adjusted to Book Value

POAI (Predictive Oncology) ROE % Adjusted to Book Value : -153.00% (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology ROE % Adjusted to Book Value?

Predictive Oncology's ROE % for the quarter that ended in Sep. 2024 was -408.51%. Predictive Oncology's PB Ratio for the quarter that ended in Sep. 2024 was 2.67. Predictive Oncology's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -153.00%.


Predictive Oncology ROE % Adjusted to Book Value Historical Data

The historical data trend for Predictive Oncology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology ROE % Adjusted to Book Value Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -361.78 -67.97 -59.11 -74.76 -57.48

Predictive Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -86.50 -86.14 -106.96 -215.39 -153.00

Competitive Comparison of Predictive Oncology's ROE % Adjusted to Book Value

For the Medical Instruments & Supplies subindustry, Predictive Oncology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's ROE % Adjusted to Book Value falls into.



Predictive Oncology ROE % Adjusted to Book Value Calculation

Predictive Oncology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-93.11% / 1.62
=-57.48%

Predictive Oncology's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-408.51% / 2.67
=-153.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Predictive Oncology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology Business Description

Traded in Other Exchanges
N/A
Address
No.91 43rd Street, Suite 110, Pittsburgh, PA, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121